Evidence map›Paper›PMID 30642428›Full record

ReviewDeutsches Arzteblatt international2018

The Investigation of Hematuria.

Christian Bolenz, Bernd Schröppel, Andreas Eisenhardt, Bernd J Schmitz-Dräger, Marc-Oliver Grimm

Abstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 89 citations in OpenAlex.

  1. Urologic oncologic emergencies: a radiologist's guide.Abdominal radiology (New York) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Christian BolenzDepartment of Urology and Pediatric Urology, University Hospital Ulm; Clinic of Internal Medicine I, Nephrology Division, University Hospital Ulm; Praxisklinik Urologie Rhein Ruhr, Mülheim an der Ruhr; Clinic for Urology, Pediatric Oncology and Oncology, Essen University Hospital; Division of Urologic Oncology, Department of Urology, St. Theresienkrankenhaus, Nürnberg and Department of Urology and Pediatric Urology at Erlangen University; Clinic for Urology, Jena University Hospital.
Bernd Schröppel
Andreas Eisenhardt
Bernd J Schmitz-Dräger
Marc-Oliver Grimm
University Hospital Ulm · DEEssen University Hospital · DEMalteser Waldkrankenhaus Erlangen · DERuhr West University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematuria can be either grossly visible (macrohematuria) or only detectable under a microscope (microhematuria). Microhematuria is often asymptomatic and has a prevalence of 4-5% in routine clinical practice. It may be due to an underlying disease of the kidneys or the urogenital tract. In this article, we provide an overview of the causes of hematuria and of the recommendations of current guidelines for its diagnostic evaluation. A risk-adapted diagnostic strategy for the evaluation of asymptomatic microhematuria (aMH) is presented.

methodsThis review is based on pertinent publications retrieved by a selective search in PubMed, as well as on guidelines from Germany and abroad.

resultsHematuria has many causes, and a broad urological and nephrological differential diagnosis must be considered. In the absence of high-quality scientific evidence, the recommendations of current guidelines for the diagnostic evaluation of hematuria are not uniform; this is particularly so for aMH. Microhematuria is said to be present when urine microscopy reveals three or more erythrocytes per highpower field. The basic diagnostic evaluation consists of a thorough history and physical examination, measurement of inflammatory parameters and renal function tests, and ultrasonography of the kidneys and bladder. Patients with non-glomerular aMH who have risk factors such as smoking, advanced age, and male sex are more likely to have relevant underlying conditions and should therefore undergo augmented, risk-adapted diagnostic evaluation with urethrocystoscopy, urine cytology, and, when indicated, CT urography. Patients with isolated glomerular hematuria are at elevated risk for renal disease and should undergo follow-up checks at six-month intervals.

conclusionAlthough hematuria is common, there is no uniform, internationally accepted, evidence-based algorithm for its diagnostic evaluation. All potential causes of hematuria must be considered, and all individual risk factors taken into account, so that an underlying disease requiring treatment can be identified or ruled out.

Indexed as

Practice Guidelines as TopicDiagnostic Techniques and ProceduresGermanyHematuriaHumansRisk Factors

Identifiers

PMID30642428
PMCPMC6365675
OpenAlexW2901280975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.